European Penny Stocks Under €200M Market Cap To Consider

The European market has experienced volatility recently, influenced by Middle East tensions and a more hawkish stance from the European Central Bank. Amid these broader economic shifts, penny stocks—often representing smaller or newer companies—continue to capture investor interest due to their potential for growth at lower price points. While the term "penny stocks" may seem outdated, these investments can still offer significant opportunities when backed by strong financials and solid fundamentals.

We'll examine a selection from our screener results.

Genetic Analysis (DB:8V8)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Genetic Analysis AS is a science-based diagnostic company focused on the research, development, manufacturing, and sale of diagnostic test solutions for the human microbiome across the United States, Europe, and internationally with a market cap of €36.62 million.

Operations: The company's revenue is primarily derived from the sale of diagnostic kits and equipment, totaling NOK 20.34 million.

Market Cap: €36.62M

Genetic Analysis AS, with a market cap of €36.62 million, offers diagnostic solutions for the human microbiome and has recently seen significant developments in its intellectual property portfolio and product launches. The Canadian patent approval enhances its position in microbiome-based diagnostics, potentially improving treatment strategies for IBS. Despite being unprofitable with a negative return on equity of -62.38%, the company maintains a stable cash runway exceeding one year and has not significantly diluted shareholders recently. However, it faces challenges such as increased debt levels and volatility in share price while revenues remain modest at NOK 20 million annually.

• Click here to discover the nuances of Genetic Analysis with our detailed analytical financial health report.
• Evaluate Genetic Analysis' historical performance by accessing our past performance report.

Greenland Resources (DB:M0LY)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Greenland Resources Inc. is a mining company focused on acquiring, exploring, and developing mineral projects in Greenland with a market cap of €126.70 million.

Operations: Currently, there are no reported revenue segments for this mining company focused on mineral projects in Greenland.

Market Cap: €126.7M

Greenland Resources Inc., with a market cap of €126.70 million, is focused on developing mineral projects in Greenland and remains pre-revenue. Recent developments include significant fieldwork at the Malmbjerg project, supported by a non-repayable contribution from the Canadian government to explore rare earth elements and magnesium recovery. The company has no debt and maintains sufficient cash runway for over a year despite being unprofitable with volatile share prices. The ongoing feasibility studies aim to optimize molybdenum production, potentially aligning with EU strategic interests in reducing reliance on Chinese imports for critical minerals.

• Dive into the specifics of Greenland Resources here with our thorough balance sheet health report.
• Review our historical performance report to gain insights into Greenland Resources' track record.

Cabka (ENXTAM:CABKA)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Cabka N.V. manufactures and sells pallets and large containers made from recycled plastic across Europe, North America, and internationally, with a market cap of €52.39 million.

Operations: The company's revenue is primarily derived from its RTP Europe segment at €133.36 million, followed by RTP US at €20.92 million, Eco Products at €14.48 million, and Recycling Fees contributing €12.38 million.

Market Cap: €52.39M

Cabka N.V., with a market cap of €52.39 million, has shown revenue growth, reporting €95.8 million for the first half of 2026 compared to €86.5 million the previous year. Despite being unprofitable, it achieved a net income of €1.2 million versus a net loss previously, indicating financial improvement. The company trades at good value relative to peers and is expected by analysts to see significant price appreciation. While its debt levels remain high with a net debt to equity ratio of 122.3%, Cabka's short-term assets cover both short- and long-term liabilities, providing some financial stability amidst volatility in share prices.

• Click to explore a detailed breakdown of our findings in Cabka's financial health report.
• Explore Cabka's analyst forecasts in our growth report.

Taking Advantage

• Access the full spectrum of 263 European Penny Stocks by clicking on this link.
• Seeking Other Investments? AI is about to change healthcare. These 126 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com